drugset / Trial / NCT02013310

HT-0712 vs. Placebo in Subjects With Age-Associated Memory Impairment (AAMI)

NCT02013310 ↗

Phase 2 Completed 119 enrolled Dart NeuroScience, LLC
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a Phase 2 randomized, multicenter, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy of HT-0712 in improving memory and cognitive performance in subjects with Age-Associated Memory Impairment (AAMI)

Timeline

Start
2013-12
Primary completion
2015-01
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Subject HT-0712 Small molecule 50 mg —